The Dawning of the Life Sciences Defense Industry
To former SmithKline Beecham R&D head George Poste, the engagement of government and industry to combat biothreats is not a matter of choice or even enlightened self-interest, but an imperative. For the past five years, he has been participating in the activities of the US Defense Science Board and engaging industry on the subject of bioterrorism and the broader issue of the spread of infectious disease. In an extensive interview with IN VIVO, he argues for creation of a life sciences defense industry--a closer and deeper relationship between government and the private sector that will mean a loss of innocence for the historically open life sciences culture. And he says government must address the lack of adequate incentives, which has discouraged private-sector participation in the past.
You may also be interested in...
Built on technology from the lab of Nobel laureate Paul Greengard, PhD, Intra-Cellular Therapies Inc. aims to develop small-molecule compounds that modify intracellular responses to endogenous neurotransmitters as therapeutics for Parkinson's disease, depression, schizophrenia and other CNS disorders.
2001 was a mixed year for health-care manufacturers, characterized by real advances in cardiac device therapies, the maturing of the biotech and generics sectors, and the continued embattlement of Big Pharma. Here's the staff of IN VIVO's list of the most important trends.
Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.